Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands

C.M.F. Kruijtzer; J. Verweij; J.H.M. Schellens; J.H. Beijnen; L. Pronk; M. Bo; V. Lustig; H. van Tinteren; M. MacKay; W.W. ten Bokkel Huinink

Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands

C.M.F. Kruijtzer
, J. Verweij
, J.H.M. Schellens
, J.H. Beijnen
, L. Pronk
, M. Bo
, V. Lustig
, H. van Tinteren
, M. MacKay
, W.W. ten Bokkel Huinink

extern

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	249-255
Number of pages	7
Journal	Anti-Cancer Drugs
Volume	11
Publication status	Published - 2000

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

@article{f3c7713d548f4309a2f0716bfd1222e7,

title = "Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands",

author = "C.M.F. Kruijtzer and J. Verweij and J.H.M. Schellens and J.H. Beijnen and L. Pronk and M. Bo and V. Lustig and \{van Tinteren\}, H. and M. MacKay and \{ten Bokkel Huinink\}, W.W.",

year = "2000",

language = "Undefined/Unknown",

volume = "11",

pages = "249--255",

journal = "Anti-Cancer Drugs",

issn = "0959-4973",

publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands

AU - Kruijtzer, C.M.F.

AU - Verweij, J.

AU - Schellens, J.H.M.

AU - Beijnen, J.H.

AU - Pronk, L.

AU - Bo, M.

AU - Lustig, V.

AU - van Tinteren, H.

AU - MacKay, M.

AU - ten Bokkel Huinink, W.W.

PY - 2000

Y1 - 2000

M3 - Article

SN - 0959-4973

VL - 11

SP - 249

EP - 255

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

ER -